Elizabeth A Grammer Ardelyx, Inc. (ARDX) insider trading activity

Elizabeth A Grammer is Officer of ARDELYX, INC.. Currently has a direct ownership of 305,890 shares of ARDX, which is worth approximately $1.62 Million. The most recent transaction as insider was on Jan 06, 2022, when has been sold 42,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 306K

1.87% 3M change

59.0% 12M change

Total Value Held $1.62 Million

ELIZABETH A GRAMMER Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 06 2022	BUY Grant, award, or other acquisition	-	42,000 Added 11.67%	317,958 Common Stock
Nov 22 2021	SELL Open market or private sale	$532 $0.99 p/Share	537 Reduced 0.19%	275,958 Common Stock
Nov 12 2021	SELL Open market or private sale	$86,724 $1.12 p/Share	77,432 Reduced 21.88%	276,495 Common Stock
Oct 08 2021	SELL Grant, award, or other acquisition	-	250,000 Reduced 41.4%	353,927 Common Stock
Aug 20 2021	SELL Open market or private sale	$694 $1.32 p/Share	526 Reduced 0.51%	102,386 Common Stock
May 20 2021	SELL Open market or private sale	$3,602 $7.09 p/Share	508 Reduced 0.49%	102,912 Common Stock
Feb 22 2021	SELL Open market or private sale	$3,468 $6.88 p/Share	504 Reduced 0.48%	103,420 Common Stock
Jan 05 2021	BUY Grant, award, or other acquisition	-	32,612 Added 23.89%	103,924 Common Stock
Dec 15 2020	SELL Bona fide gift	-	1,215 Reduced 1.68%	71,312 Common Stock
Dec 14 2020	SELL Open market or private sale	$299,300 $7.3 p/Share	41,000 Reduced 36.11%	72,527 Common Stock
Dec 14 2020	BUY Exercise of conversion of derivative security	$95,120 $2.32 p/Share	41,000 Added 26.53%	113,527 Common Stock
Dec 11 2020	SELL Open market or private sale	$7,300 $7.3 p/Share	1,000 Reduced 1.36%	72,527 Common Stock
Dec 11 2020	BUY Exercise of conversion of derivative security	$2,320 $2.32 p/Share	1,000 Added 1.34%	73,527 Common Stock

Also insider at

SGMT

Sagimet Biosciences Inc.

Director

EAG